Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), is often accompanied by injury to pulmonary function and pulmonary fibrosis. Feiluoning (FLN) is a new Chinese medicine prescription which is available for the treatment of severe and critical convalescence of COVID-19 patients. FLN also has a positive effect on pulmonary function injury and pulmonary fibrosis. We explored the potential mechanism of FLN’s effect on the convalescent treatment of COVID-19. According to the pharmacodynamic activity parameters, we screened the active chemical constituents of FLN by comparing the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. The Uniprot database was used to querying the corresponding target genes, and Cytoscape 3.6.1 was used to construct a herb-compound-target network. Protein interaction analysis, target gene function enrichment analysis, and signal pathway analysis were performed using the STRING, DAVID, and Kyoto Encyclopedia of Genes and Genomes pathway databases. Molecular docking was used to predict the binding capacity of the core compound with COVID-19 hydrolase 3 Cl and angiotensin-converting enzyme 2 (ACE2). The herb-compound-target network was successfully constructed and key targets identified, including prostaglandin G/H synthase 2, estrogen receptor 1, heat shock protein HSP 90, and androgen receptor. The major affected metabolic pathways were pathways in cancer, pancreatic cancer, nonsmall cell lung cancer, and toll-like receptor signaling. The core compounds of FLN, including quercetin, luteolin, kaempferol, and stigmasterol, could strongly bind to COVID-19 3 Cl hydrolase, and other compounds, including 7-O-methylisomucronulatol and medicocarpin, could strongly bind to ACE2. Thus, it is predicted that FLN has the characteristics of a multicomponent, multitarget, and multichannel overall control compound. FLN’s mechanism of action in the treatment of COVID-19 may be associated with the regulation of inflammation and immune-related signaling pathways, and the influence of COVID-19 3 Cl hydrolase binding ability.

由严重的急性呼吸综合征-冠状病毒2（SARS-CoV-2）引起的冠状病毒病2019（COVID-19）通常伴随肺功能和肺纤维化损伤。非洛宁（FLN）是一种新的中药处方，可用于治疗COVID-19患者的严重和重度康复。FLN对肺功能损伤和肺纤维化也有积极作用。我们探讨了FLN对COVID-19的康复治疗的潜在机制。根据药效学活性参数，通过比较中药系统药理数据库和分析平台，筛选了FLN的活性化学成分。Uniprot数据库用于查询相应的靶基因和Cytoscape 3.6。1用于构建草药-化合物-靶标网络。使用STRING，DAVID和Kyoto Encyclopedia of Genes and Genomes通路数据库进行了蛋白质相互作用分析，靶基因功能富集分析和信号通路分析。分子对接用于预测核心化合物与COVID-19水解酶3 Cl和血管紧张素转化酶2（ACE2）的结合能力。成功构建了草药-化合物-靶标网络并确定了主要靶标，包括前列腺素G / H合酶2，雌激素受体1，热休克蛋白HSP 90和雄激素受体。受影响的主要代谢途径是癌症，胰腺癌，非小细胞肺癌和通行费样受体信号传导途径。FLN的核心化合物包括槲皮素，木犀草素，山奈酚和豆甾醇，可以与COVID-19 3 Cl水解酶牢固结合，而其他化合物（包括7-O-甲基异粘核酸和麦考林）可以与ACE2牢固结合。因此，预测FLN具有多组分，多靶标和多通道总体控制化合物的特征。FLN在治疗COVID-19中的作用机制可能与炎症和免疫相关信号通路的调节以及COVID-19 3 Cl水解酶结合能力的影响有关。